ArriVent BioPharma, Inc. AVBP Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s unrealized gains (losses) on available-for-sale securities?
- ArriVent BioPharma, Inc. (AVBP) reported unrealized gains (losses) on available-for-sale securities of -$284K in Q1 2026.
- How has ArriVent BioPharma, Inc.'s unrealized gains (losses) on available-for-sale securities changed year-over-year?
- ArriVent BioPharma, Inc.'s unrealized gains (losses) on available-for-sale securities decreased by 246.4% year-over-year, from $194K to -$284K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric represents the change in fair value of available-for-sale debt or equity securities that have not yet been realized through a sale. It reflects market-driven fluctuations in the value of the company's investment portfolio that are recognized in equity rather than the income statement. Monitoring this helps investors assess the volatility and unrealized performance of the company's treasury or strategic investment holdings.